User: Guest  Login
Document type:
journal article 
Author(s):
Sanchez-Vega, Francisco; Hechtman, Jaclyn F; Castel, Pau; Ku, Geoffrey Y; Tuvy, Yaelle; Won, Helen; Fong, Christopher J; Bouvier, Nancy; Nanjangud, Gouri J; Soong, Joanne; Vakiani, Efsevia; Schattner, Mark; Kelsen, David P; Lefkowitz, Robert A; Brown, Karen; Lacouture, Mario E; Capanu, Marinela; Mattar, Marissa; Qeriqi, Besnik; Cecchi, Fabiola; Tian, Yuan; Hembrough, Todd; Nagy, Rebecca J; Lanman, Richard B; Larson, Steven M; Pandit-Taskar, Neeta; Schöder, Heiko; Iacobuzio-Donahue, Christine A;...    »
 
Title:
and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. 
Abstract:
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an irreversible pan-HER kinase inhibitor, in trastuzumab-resistant EG cancer. We analyzed pretreatment tumor biopsies and, in select cases, performed comprehensive characterization of postmortem metastatic specimens following acquisition of drug resistance. Afatinib r...    »
 
Journal title abbreviation:
Cancer Discov 
Year:
2019 
Journal volume:
Journal issue:
Pages contribution:
199-209 
Language:
eng 
Print-ISSN:
2159-8274 
TUM Institution:
Klinik und Poliklinik für Nuklearmedizin